Elutia, Inc. Stock Plummets to New 52-Week Low of $1.08

Elutia, Inc., a microcap player in the Pharmaceuticals & Biotechnology sector, has reached a new 52-week low of USD 1.08 on September 18, 2025. This significant decline reflects a challenging year for the company, which has seen its stock price plummet by 68.88% over the past year, starkly contrasting with the S&P 500's performance of 17.14% during the same period.
The company's market capitalization stands at approximately USD 80 million, and it currently operates without a dividend yield. Elutia's financial metrics indicate a negative book value, which raises concerns about its long-term fundamental strength. The company has reported a troubling annual decline in net sales of 15.13% and an operating profit decrease of 24.32% over the last five years.

Additionally, Elutia's operating cash flow has reached a low of USD -32.8 million, with pre-tax and net profits also reflecting significant losses. The company's high debt-to-EBITDA ratio further complicates its financial standing, highlighting its low ability to service debt. Overall, Elutia, Inc. is navigating a period of notable financial difficulties, as evidenced by its recent stock performance and underlying metrics.